Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).
Elessa D, Zhao LP, de Oliveira RD, Maslah N, Soret-Dulphy J, Verger E, Marcault C, Parquet N, Fenaux P, Adès L, Raffoux E, Giraudier S, Fain O, Cassinat B, Kiladjian JJ, Mekinian A, Benajiba L. Elessa D, et al. Among authors: giraudier s. Leukemia. 2023 Aug;37(8):1741-1744. doi: 10.1038/s41375-023-01967-0. Epub 2023 Jul 11. Leukemia. 2023. PMID: 37433887 No abstract available.
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.
Gautier EF, Picard M, Laurent C, Marty C, Villeval JL, Demur C, Delhommeau F, Hexner E, Giraudier S, Bonnevialle N, Ducommun B, Récher C, Laurent G, Manenti S, Mansat-De Mas V. Gautier EF, et al. Among authors: giraudier s. Blood. 2012 Feb 2;119(5):1190-9. doi: 10.1182/blood-2011-01-327742. Epub 2011 Nov 7. Blood. 2012. PMID: 22065597 Free article.
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Pecquet C, Diaconu CC, Staerk J, Girardot M, Marty C, Royer Y, Defour JP, Dusa A, Besancenot R, Giraudier S, Villeval JL, Knoops L, Courtoy PJ, Vainchenker W, Constantinescu SN. Pecquet C, et al. Among authors: giraudier s. Blood. 2012 May 17;119(20):4625-35. doi: 10.1182/blood-2011-08-372524. Epub 2012 Feb 29. Blood. 2012. PMID: 22378845 Free article.
Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S. Gannagé M, et al. Among authors: giraudier s. J Immunol. 2005 Jun 15;174(12):8210-8. doi: 10.4049/jimmunol.174.12.8210. J Immunol. 2005. PMID: 15944330
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators. Porter JB, et al. Eur J Haematol. 2011 Oct;87(4):338-48. doi: 10.1111/j.1600-0609.2011.01660.x. Epub 2011 Jul 29. Eur J Haematol. 2011. PMID: 21649735 Free PMC article. Clinical Trial.
Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression.
Komura E, Tonetti C, Penard-Lacronique V, Chagraoui H, Lacout C, Lecouédic JP, Rameau P, Debili N, Vainchenker W, Giraudier S. Komura E, et al. Among authors: giraudier s. Cancer Res. 2005 Apr 15;65(8):3281-9. doi: 10.1158/0008-5472.CAN-04-2339. Cancer Res. 2005. PMID: 15833861
A new c-kit mutation in a case of aggressive mast cell disease.
Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M. Pignon JM, et al. Among authors: giraudier s. Br J Haematol. 1997 Feb;96(2):374-6. doi: 10.1046/j.1365-2141.1997.d01-2042.x. Br J Haematol. 1997. PMID: 9029028 Free article.
133 results